Association between NQO1 C609T polymorphism and bladder cancer susceptibility: A systemic review and meta-analysis

Tumor Biology

Volumn 34, Issue 5, 2013, Pages 2551-2556

  Gong, Min ^a   Yi, Qingtong ^a   Wang, Weiming ^b  

^a FUDAN UNIVERSITY PUDONG MEDICAL CENTER   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Bladder cancer; Meta analysis; NQO1; Polymorphism

Indexed keywords

EID: 84885405199     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0799-7     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374:239-49.
3. Mitra AP, Cote RJ. Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol. 2009;4:251-85.
4. Wu X, Hildebrandt MA, Chang DW. Genome-wide association studies of bladder cancer risk: a field synopsis of progress and potential applications. Cancer Metastasis Rev. 2009;28:269-80.
5. Golka K, Selinski S, Lehmann ML, Blaszkewicz M, Marchan R, Ickstadt K, et al. Genetic variants in urinary bladder cancer: collective power of the "wimp SNPs". Arch Toxicol. 2011;85:539-54.
6. Vasiliou V, Ross D, Nebert DW. Update of the NAD(P)H:quinone oxidoreductase (NQO) gene family. Hum Genomics. 2006;2:329-35.
7. Ross D, Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol. 2004;382:115-44.
8. Guha N, Chang JS, Chokkalingam AP, Wiemels JL, Smith MT, Buffler PA. NQO1 polymorphisms and de novo childhood leukemia: a huge review and meta-analysis. Am J Epidemiol. 2008;168:1221-32.
9. Siegel D, Yan C, Ross D. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol. 2012;83:1033-40.
10. Misra V, Grondin A, Klamut HJ, Rauth AM. Assessment of the relationship between genotypic status of a DT-diaphorase point mutation and enzymatic activity. Br J Cancer. 2000;83:998-1002.
11. Siegel D, McGuinness SM, Winski SL, Ross D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics. 1999;9:113-21.
12. Wang YH, Lee YH, Tseng PT, Shen CH, Chiou HY. Human NAD(P)H:quinone oxidoreductase 1 (NQO1) and sulfotransferase 1A1 (SULT1A1) polymorphisms and urothelial cancer risk in Taiwan. J Cancer Res Clin Oncol. 2008;134:203-9.
13. Terry PD, Umbach DM, Taylor JA. No association between SOD2 or NQO1 genotypes and risk of bladder cancer. Cancer Epidemiol Biomark Prev. 2005;14:753-4.
14. Schulz WA, Krummeck A, Rosinger I, Eickelmann P, Neuhaus C, Ebert T, et al. Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics. 1997;7:235-9.
15. Sanyal S, Festa F, Sakano S, Zhang Z, Steineck G, Norming U, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004;25:729-34.
16. Park SJ, Zhao H, Spitz MR, Grossman HB, Wu X. An association between NQO1 genetic polymorphism and risk of bladder cancer. Mutat Res. 2003;536:131-7.
17. Moore LE, Wiencke JK, Bates MN, Zheng S, Rey OA, Smith AH. Investigation of genetic polymorphisms and smoking in a bladder cancer case-control study in Argentina. Cancer Lett. 2004;211:199-207.
18. Hung RJ, Boffetta P, Brennan P, Malaveille C, Gelatti U, Placidi D, et al. Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk. Carcinogenesis. 2004;25:973-8.
19. Fu J, Chen BC. Relationship between genetic polymorphism of NQO1 and susceptibility to bladder cancer. J Chin Oncol. 2012;18:561-4.
20. Figueroa JD, Malats N, Garcia-Closas M, Real FX, Silverman D, Kogevinas M, et al. Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis. 2008;29:1955-62.
21. Choi JY, Lee KM, Cho SH, Kim SW, Choi HY, Lee SY, et al. CYP2E1 and NQO1 genotypes, smoking and bladder cancer. Pharmacogenetics. 2003;13:349-55.
22. Broberg K, Bjork J, Paulsson K, Hoglund M, Albin M. Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis. 2005;26:1263-71.
23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
24. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
25. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
26. Galbraith R. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med. 1988;7:889-94.
27. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34.
28. Kiltie AE. Common predisposition alleles for moderately common cancers: bladder cancer. Curr Opin Genet Dev. 2010;20:218-24.
29. Han SS, Rosenberg PS, Garcia-Closas M, Figueroa JD, Silverman D, Chanock SJ, et al. Likelihood ratio test for detecting gene (G)-environment (E) interactions under an additive risk model exploiting G-E independence for case-control data. Am J Epidemiol. 2012;176:1060-7.
30. Boffetta P, Winn DM, Ioannidis JP, Thomas DC, Little J, Smith GD, et al. Recommendations and proposed guidelines for assessing the cumulative evidence on joint effects of genes and environments on cancer occurrence in humans. Int J Epidemiol. 2012;41:686-704.
31. Panagiotakis GI, Papadogianni D, Chatziioannou MN, Lasithiotaki I, Delakas D, Spandidos DA. Association of human herpes, papilloma and polyoma virus families with bladder cancer. Tumour Biol. 2013;34:71-9.
32. Zhang Y, Wang X, Zhang W, Gong S. An association between XPC Lys939Gln polymorphism and the risk of bladder cancer: a meta-analysis. Tumour Biol. 2013;34:973-82.
33. Fan R, Zhong M, Wang S, Zhang Y, Andrew A, Karagas M, et al. Entropy-based information gain approaches to detect and to characterize gene-gene and gene-environment interactions/correlations of complex diseases. Genet Epidemiol. 2011;35:706-21.